Cart
sales@molnova.com
Mitazalimab
CAS No. 2055640-86-1
Mitazalimab( —— )
Catalog No. M36813 CAS No. 2055640-86-1
Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that targets tumors by activating antigen-presenting cells like dendritic cells (DC), initiating tumor-reactive T cells, promoting tumor-specific T cell infiltration and destruction of tumors, and remodeling the tumor-infiltrating myeloid microenvironment .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1454 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2595 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMitazalimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that targets tumors by activating antigen-presenting cells like dendritic cells (DC), initiating tumor-reactive T cells, promoting tumor-specific T cell infiltration and destruction of tumors, and remodeling the tumor-infiltrating myeloid microenvironment .
-
DescriptionMitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
-
In Vitro——
-
In VivoAnimal Model:MB49-tumor bearing mice model Dosage:10, 30, 100 or 300 μg/mouse Administration:Intraperitoneal injection; on day 7, 10 and 13 post-inoculation; sampled at 24 h after final dose Result: Increased the level of IP-10, MIP-1α and TNF-α, but not CXCL1, IFN-γ, IL-6, IL-10, MCP-1 and MIP-2.Resulted in increased frequency of CD44hi CD62L-efector memory CD8+ and CD4+ T cells.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2055640-86-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. ?
molnova catalog
related products
-
AS-85
AS-85, a potent inhibitor of ASH1L histone methyltransferase (IC50 = 0.6 μM), exhibits anti-leukemic activity by strongly binding to the ASH1L SET domain (Kd = 0.78 μM).
-
Ursodeoxycholic Acid...
Ursodeoxycholic Acid-d4 (Ursodeoxycholic acid-2,2,4,4-d4) is the deuterium substitute of Ursodeoxycholic acid, and is an internal standard for the quantitative determination of Ursodeoxycholic Acid (UDCA) levels by LC/MS or GC/MS.
-
R715 TFA(185052-09-9...
Potent and selective bradykinin B1 receptor antagonist (pA2 = 8.49). Displays no activity at B2 receptors. Reduces mechanical hypernociception in a mouse model of neuropathic pain. Metabolically stable.
